High RCN1 expression affects the sensitivity of hepatocellular carcinoma cells to sorafenib, while decreasing RCN1 content increases cellular sensitivity to antitumor drugs, such as adriamycin in uterine sarcoma cells and nasopharyngeal carcinoma cells [26, 55]. Here, RCN1 is linked to nasopharyngeal carcinoma.